Amarin Corp. Plc (AMRN)
11.37
-0.30
(-2.57%)
USD |
NASDAQ |
Nov 13, 16:00
11.37
0.00 (0.00%)
After-Hours: 19:50
Amarin EPS Diluted (Quarterly) : 0.0114 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0114 |
| June 30, 2026 | -0.3681 |
| March 31, 2026 | -0.501 |
| December 31, 2025 | -0.0587 |
| September 30, 2025 | -0.3701 |
| June 30, 2025 | -0.6906 |
| March 31, 2025 | -0.7623 |
| December 31, 2024 | -2.342 |
| September 30, 2024 | -0.0618 |
| June 30, 2024 | 0.0037 |
| March 31, 2024 | -0.0243 |
| December 31, 2023 | -0.0143 |
| September 30, 2023 | -0.047 |
| June 30, 2023 | -0.0432 |
| March 31, 2023 | -0.0409 |
| December 31, 2022 | 0.0021 |
| September 30, 2022 | -0.0126 |
| June 30, 2022 | -0.1742 |
| March 31, 2022 | -0.0789 |
| December 31, 2021 | 0.0366 |
| September 30, 2021 | -0.033 |
| June 30, 2021 | 0.0194 |
| March 31, 2021 | -0.0041 |
| December 31, 2020 | 0.0125 |
| September 30, 2020 | -0.0177 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.0111 |
| March 31, 2020 | -0.0569 |
| December 31, 2019 | 0.0179 |
| September 30, 2019 | -0.0098 |
| June 30, 2019 | -0.0055 |
| March 31, 2019 | -0.0751 |
| December 31, 2018 | -0.1063 |
| September 30, 2018 | -0.0829 |
| June 30, 2018 | -0.1185 |
| March 31, 2018 | -0.0805 |
| December 31, 2017 | -0.0811 |
| September 30, 2017 | -0.0402 |
| June 30, 2017 | -0.051 |
| March 31, 2017 | -0.0765 |
| December 31, 2016 | -0.0912 |
| September 30, 2016 | -0.0737 |
| June 30, 2016 | -0.067 |
| March 31, 2016 | -0.1503 |
| December 31, 2015 | -0.1193 |
| September 30, 2015 | -0.1791 |
| June 30, 2015 | -0.3431 |
| March 31, 2015 | -0.1685 |
| December 31, 2014 | -0.1094 |
| September 30, 2014 | -0.1709 |
| June 30, 2014 | 0.0835 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| DBV Technologies SA | -0.7143 |
| Akari Therapeutics Plc | -2.404 |
| Cellectis SA | -0.2165 |
| Alkermes Plc | 0.0924 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.2449M |
| Revenue (Quarterly) | 39.53M |
| Total Expenses (Quarterly) | 39.29M |
| Enterprise Value | -72.20M |
| Gross Profit Margin (Quarterly) | 39.30% |
| Profit Margin (Quarterly) | 0.62% |
| Earnings Yield | -8.06% |
| Normalized Earnings Yield | -5.871 |